CSIRO Successful completion of first milestone
In August 2012 MVP announced it had entered into a research and development program with the CSIRO designed to introduce a new, more efficient, significantly lower manufacturing cost process for the pharmaceutical compound used in Penthrox?. We are delighted to announce the first milestone, which is to manufacture commercial grade methoxyflurane in much larger quantities than at present, has been achieved. This is an important milestone for MVP and, should the program conclude successfully, the result will be that MVP will have a world first, proprietary manufacturing process for methoxyflurane, which will increase manufacturing capacity while significantly reducing our cost of goods sold.